Myriad Genetics, Inc.

Submit Your Information

Company Name	Myriad Genetics, Inc.
Stock Symbol	MYGN

On May 6, 2025, Myriad released its first quarter 2025 financial results, revealing “revenue of $196 million declined by 3% year-over-year” and “pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.” Additionally, the Company announced reduced finanical guidance for 2025 “reflecting first quarter 2025 results and the current business outlook.”

On this news, Myriad’s stock price fell $3.00, or 41.3%, to close at $4.27 per share on May 7, 2025, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Myriad Genetics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before January 01, 1970?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments